NEUROGENE INC (NGNE)
(Real Time Quote from BATS)
$38.26 USD
+0.53 (1.41%)
Updated Jun 5, 2024 12:35 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Neurogene Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -36.32 | -57.56 | -60.69 | -33.28 | -69.44 |
Depreciation/Amortization & Depletion | 3.19 | 2.12 | 2.28 | 1.82 | 0.34 |
Net Change from Assets/Liabilities | -4.02 | 0.89 | -0.70 | 0.97 | -1.95 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -14.27 | 8.95 | 11.56 | 5.92 | 55.66 |
Net Cash From Operating Activities | -51.42 | -45.61 | -47.56 | -24.58 | -15.39 |
Property & Equipment | -0.32 | -1.11 | -3.26 | -2.22 | -0.88 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 |
Investments | 5.00 | -58.02 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 20.96 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 25.64 | -59.13 | -3.26 | -2.22 | -0.69 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.17 | 0.22 | 0.78 | 77.54 | 87.77 |
Issuance (Repayment) of Debt | 92.31 | -0.06 | -0.05 | -0.05 | -0.01 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | -0.36 | -5.53 |
Net Cash from Financing Activities | 92.48 | 0.16 | 0.73 | 77.14 | 82.24 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
Net Change In Cash & Equivalents | 66.70 | -104.58 | -50.09 | 50.34 | 66.17 |
Cash at Beginning of Period | 82.02 | 143.35 | 193.43 | 143.09 | 76.93 |
Cash at End of Period | 148.72 | 38.77 | 143.35 | 193.43 | 143.09 |
Diluted Net EPS | -7.80 | -20.80 | -22.00 | -12.80 | -51.40 |
Fiscal Year End for Neurogene Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -16.92 | -36.32 | -20.82 | -16.29 | -14.20 |
Depreciation/Amortization & Depletion | 0.38 | 3.19 | -0.51 | -0.19 | 0.08 |
Net Change from Assets/Liabilities | -6.75 | -4.02 | -5.23 | -5.49 | -3.71 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.64 | -14.27 | 5.21 | 4.89 | 4.80 |
Net Cash From Operating Activities | -21.65 | -51.42 | -21.35 | -17.08 | -13.03 |
Property & Equipment | -0.07 | -0.32 | 1.56 | 1.56 | -0.42 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 30.00 | 5.00 | 7.12 | 8.73 | 11.13 |
Other Investing Activities | 0.00 | 20.96 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 29.94 | 25.64 | 8.68 | 10.30 | 10.71 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.63 | 0.17 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | -0.01 | 92.31 | -0.37 | -0.36 | -0.07 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -7.14 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -6.52 | 92.48 | -0.36 | -0.36 | -0.07 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 1.76 | 66.70 | -13.03 | -7.15 | -2.39 |
Cash at Beginning of Period | 148.72 | 82.02 | 38.77 | 38.77 | 38.77 |
Cash at End of Period | 150.48 | 148.72 | 25.73 | 31.62 | 36.37 |
Diluted Net EPS | -1.00 | -0.16 | -1.64 | -0.80 | -5.20 |